PDCD1 and cutaneous melanoma: Li et al. [34] in the Guangzhou (CN) center showed that adjuvant anti-PD-1 treatment contributed to a significantly longer RFS (not reached vs. 7.8 mo) and DMFS (not reached vs. 9.4 mo; HR, 0.324; 95% CI, 0.122 to 0.861; p = 0.017) than HDI in Chinese patients with cutaneous melanoma, with the median follow-up times being 19.2 mo (PD-1) and 46.2 mo (HDI), respectively.